Safety and pharmacokinetics of meclizine hydrochloride for achondroplasia children

Safety and pharmacokinetics of meclizine hydrochloride for achondroplasia children - Safety and pharmacokinetics of meclizine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033052

Enrollment

Registered

2018-06-20

Start date

2018-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

achondroplasia

Interventions

single dose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: achondroplasia children

Exclusion criteria

Exclusion criteria: body weight of less than 11 kg

Design outcomes

Primary

Measure	Time frame
24-hour pharmacokinetics of meclizine drug accumulation adverse events and side effects	—

Secondary

Measure	Time frame
Simulation of pharmacokinetics in repeated administration of meclizine for 14 days	—

Countries

Japan

Contacts

Public ContactMasaki Matsushita

Nagoya University Hospital Orthopedic Surgery

masakim@med.nagoya-u.ac.jp052-744-2257

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026